Mostrar el registro sencillo del ítem
dc.contributor.author | Miguel, Sara de | |
dc.contributor.author | Domenech Lucas, Mirian | |
dc.contributor.author | Gonzalez-Camacho, Fernando | |
dc.contributor.author | Sempere, Julio | |
dc.contributor.author | Vicioso-Perez, Maria Dolores | |
dc.contributor.author | Sanz, Juan Carlos | |
dc.contributor.author | García Comas, Luis | |
dc.contributor.author | Ardanuy, Carmen | |
dc.contributor.author | Fenoll, Asuncion | |
dc.contributor.author | Yuste, Jose Enrique | |
dc.date.accessioned | 2020-10-28T14:03:22Z | |
dc.date.available | 2020-10-28T14:03:22Z | |
dc.date.issued | 2020-09-29 | |
dc.identifier.citation | Clin Infect Dis . 2020 Sep 29;ciaa1483. | es_ES |
dc.identifier.uri | http://hdl.handle.net/20.500.12105/11254 | |
dc.description.abstract | Introduction of pneumococcal conjugate vaccines (PCVs) has shown a marked reduction in the disease caused by vaccine serotypes in children providing herd protection to the elderly group. However, the emergence of non-vaccine serotypes is of great concern worldwide. This study includes national laboratory data from invasive pneumococcal disease (IPD) cases affecting pediatric and adult population during 2009-2019. The impact of implementing different vaccine strategies for immunocompetent adults comparing Spanish regions using PCV13 vs regions using PPV23 vaccine was also analyzed for 2017-2019. The overall reductions of IPD cases by PCV13 serotypes in children and adults were 88% and 59% respectively during 2009-2019 with a constant increase of serotype 8 in adults since 2015. IPD cases by additional serotypes covered by PPV23 increased from 20% in 2009 to 52% in 2019. In children, serotype 24F was the most frequent in 2019 whereas in adults, serotypes 3 and 8 accounted for 36% of IPD cases. Introduction of PCV13 or PPV23 in the adult calendar of certain Spanish regions reduced up to 25% and 11% respectively the IPD cases by PCV13 serotypes, showing a decrease of serotype 3 when PCV13 was used. Use of PCV13 in children has shown a clear impact in pneumococcal epidemiology reducing the burden of IPD in children but also in adults by herd protection although the increase of serotype 8 in adults is worrisome. Vaccination with PCV13 in immunocompetent adults seems to control IPD cases by PCV13 serotypes including serotype 3. | es_ES |
dc.description.sponsorship | This work was supported by Ministerio de Economía, Industria y Competitividad (MINECO) [grant SAF2017-83388] and internal funding from | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Oxford University Press | es_ES |
dc.type.hasVersion | SMUR | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-sa/4.0/ | * |
dc.subject.mesh | Streptococcus pneumoniae | es_ES |
dc.subject.mesh | IPD | es_ES |
dc.subject.mesh | Serotypes | es_ES |
dc.subject.mesh | PCV13 | es_ES |
dc.subject.mesh | PPV23 | es_ES |
dc.title | Nationwide trends of invasive pneumococcal disease in Spain (2009-2019) in children and adults during the pneumococcal conjugate vaccine era. | es_ES |
dc.type | research article | es_ES |
dc.rights.license | Atribución-NoComercial-CompartirIgual 4.0 Internacional | * |
dc.identifier.pubmedID | 32990303 | es_ES |
dc.identifier.doi | 10.1093/cid/ciaa1483 | es_ES |
dc.contributor.funder | Ministerio de Economía, Industria y Competitividad (España) | |
dc.description.peerreviewed | Sí | es_ES |
dc.identifier.e-issn | 1537-6591 | |
dc.relation.publisherversion | https://doi.org/10.1093/cid/ciaa1483 | es_ES |
dc.identifier.journal | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | es_ES |
dc.repisalud.centro | ISCIII::Centro Nacional de Microbiología | es_ES |
dc.repisalud.institucion | ISCIII | es_ES |
dc.relation.projectID | info:eu-repo/grantAgreement/ES/SAF2017-83388 | es_ES |
dc.rights.accessRights | open access | es_ES |